Glizid 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glizid 80 is typically prescribed when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose levels. The medication helps reduce both fasting and postprandial blood glucose concentrations, contributing to the prevention of long-term complications associated with diabetes, such as neuropathy, retinopathy, and nephropathy. It is important to administer Glizid 80 with meals to minimize the risk of hypoglycemia, a potential adverse effect characterized by symptoms such as dizziness, sweating, and confusion. Dose adjustment may be necessary based on individual patient response and renal function. Regular monitoring of blood glucose and periodic assessment of glycosylated hemoglobin (HbA1c) levels are recommended to evaluate therapeutic efficacy. Glizid 80 should be used cautiously in patients with hepatic or renal impairment and is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patient education on adherence and recognition of hypoglycemic symptoms is essential for optimal treatment outcomes.

Dosage & How to Use